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INTRODUCTION
Levonorgestrel (LNG) is a synthetic progestin used
for contraception either alone or in combination
with ethynyl estradiol. The preparation in LNG
administered alone is progestin only contraceptive
pills (known as mini pills), Norplant® and Jadena®
subdermal implant, and the intrauterine LNG
system (Levonova® or Mirena®).
Abstract
Objective: To provide a randomized comparison between Jadena®
and Norplant® in terms of efficacy and acceptability among Indone-
sian women.
Method: This study was a phase IV, open label, randomized, mul-
ticenter study throughout Indonesia. Subjects were Indonesian adult
women who were randomized to receive Jadena® or Norplant® as
their contraceptive method. The subjects were recruited from 6
large cities in Indonesia, such as Medan, Palembang, Jakarta, Sema-
rang, Surabaya, and Makassar.
Result: Of 600 subjects, 301 women getting to Jadena® and 299
women to Norplant® were enrolled between August 1998 and
February 1999. The mean age was 29.8 (SD 5.3) years old, ranging
from 18 to 40 years old. We did not find the pregnancy during the
study. Non-pregnancy probability at the end of one year was similar
between Jadena® (0.920 (SD 0.016)) and Norplant® users (0.916
(SD 0.084)). The continuation rates of Jadena® at one and three-year
were 95.3% and 66.8%; whereas, the continuation rates of
Norplant® was 94.3% at year-1 and 70.2% at year-3.
Conclusion: The new two rod levonorgestrel subdermal system
(Jadena®) showed similar efficacy with the old six capsule
levonorgestrel subdermal system (Norplant®) in term of birth
control. Both implant systems also have similar tolerability profile.
Jadena® is easier to insert and remove than Norplant®.
[Indones J Obstet Gynecol 2016; 4-4: 190-197]
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Abstrak
Tujuan: Untuk mengetahui efikasi dan akseptabilitas antara Jadena©
dan Norplant© di antara perempuan Indonesia.
Metode: Penelitian ini merupakan fase 4, terbuka, acak, dan multi-
senter di Indonesia. Subjek penelitian merupakan perempuan dewasaIndonesia yang teracak untuk menerima Jadena© atau Norplant©
sebagai metode kontrasepsi. Penelitian ini diambil dari 6 kota besar di
Indonesia yaitu Medan, Palembang, Jakarta, Semarang, Surabaya, danMakassar.
Hasil: Dari total 600 subjek, 301 menggunakan Jadena© dan 299
mengunakan Norplant© pada periode Agustus 1998 hingga Februari
1999. Rerata usia ialah 29,8 (SD 5,3) tahun berkisar antara 18 hingga40 tahun. Tidak ada kehamilan yang terjadi selama periode observasi.
Kemungkinan hamil setelah 1 tahun antara Jadena© (0,920 (SD
0,016)) dan Norplant© (0,916 (SD 0,084)). Angka kebertahananpenggunaan Jadena© pada tahun 1 dan tahun 3 ialah 95,3% dan
66,8%, sementara pada Norplant© ialah 94,3% dan 70,2%.
Kesimpulan: Sistem subdermal levonogestrel 2 batang (Jadena©)
memiliki efikasi yang mirip dengan sistem subdermal lamamenggunakan 6 kapsul (Norplant©) dalam mengontrol kehamilan.
Kedua sistem implan memiliki profil tolerabilitas yang serupa.
Jadena© lebih mudah dimasukkan dan dikeluarkan daripadaNorplant©.
[Maj Obstet Ginekol Indones 2016; 4-4: 190-197]
Kata kunci: efikasi,implan, kontrol kehamilan
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Levonorgestrel primarily acts through thicken-
ing the cervical mucus; thus, it will obstruct the
sperm penetration into the uterus.1,2 Besides, it
also inhibits ovulation in over 50% of the mens-
trual cycles3,4 and has a suppressive effect on the
endometrium to reduce the likelihood of nidation.5
Both mechanism of action above provide protec-
tion against pregnancy efficiently.
The beneficial features of Norplant® include
long contraceptive activity, high contraceptive effi-
cacy, absence of estrogen side effects, and conve-
nience due to no daily attention needed. Further-
more, it is completely reversible and the side-
effects are mainly mild and transient. Norplant®
capsules have been studied extensively for clinical
efficacy and safety by independent clinicians and
agencies throughout the world for many years.
However, insertion and removal of the implant
needs sufficient training.
On the other hand, Jadena® is developed as two
implantable rods in order to make insertion and
removal of the contraceptive device easier. Both
the release rate of LNG from Jadena® rods and
plasma hormone concentrations achieved are com-
parable to those of the Norplant® capsules.6,7 The
two preparations are similar in terms of contracep-
tive efficacy for three years and the occurrence of
side effects.8-10
Jadena® is a subdermal tube implant containing
75 mg of LNG each, whereas Norplant® is a sub-
dermal capsule containing 36 mg LNG each.
Jadena® implant consists of two rods sizing nine
millimeters longer than the Norplant® capsules.
The period of Jadena® rod user is for three years;
meanwhile, the Norplant® capsules provide longer
period for five years of effective contraceptive
protection.
Norplant® was introduced into the Family
Planning Program (FPP) in Indonesia since 1981.
It becomes popular among Indonesian commu-
nity.9 By March 1997, there were 2.4 million
women using Norplant® as their contraceptive
method in Indonesia. This represents about three
quarters of Norplant® users all over the world.
Recently, Jadena® was also registered in Indonesia
and it had already been used by about 2,000 Indo-
nesian women. However, data comparing the
efficacy and acceptability of Norplant® and
Jadena® are still not available in Indonesia. There-
fore, this study aims to provide a randomized
comparison between Jadena® and Norplant® in
terms of efficacy and acceptability among Indone-
sian women.
METHODS
This study was a phase IV, open label, randomized,
and multicenter studies throughout Indonesia.
Subjects were recruited from 6 large cities in Indo-
nesia, namely Medan (Universitas Sumatera Utara),
Palembang (Universitas Sriwijaya), Jakarta (Uni-
versitas Indonesia), Semarang (Universitas Dipo-
negoro), Surabaya (Universitas Airlangga) and
Makassar (Universitas Hasanuddin) between
August 1998 and February 1999.
Subjects were Indonesian adult women having
been randomized to receive Jadena® or Norplant®
as their contraceptive method. The sample size was
determined through formula proposed by Pocock.
To demonstrate a ten-fold increase in cumulative
3-year pregnancy rate (0.5 per 100 women-years),
the minimum sample size was 272 subjects per
treatment group.
A total of 600 women were needed which meant
100 women recruited from each center. This study
was the first design to be followed-up for three
years; however, another 2 years were added to
complete 5-year observation and follow-up. Sub-
jects were followed every year in 12 visits, such as
at month-1, 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, and
60. We recruited 18-40-year old women, not cur-
rently pregnant, be regularly exposed to the risk of
pregnancy, without exposure to injectable steroid
in the predicting 6 months, be willing to rely solely
on the implant randomly assigned for her contra-
ceptive method, be willing to return the clinic for
regular follow-up. All the participants were in-
formed of the purpose, risk, and benefits of the
study and they had to sign the written informed
consent.
Subjects were excluded from the study if there
was any kind of cancers, undiagnosed abnormal
uterine bleeding (AUB); thromboembolism or se-
vere cardiovascular problem; mental illness, de-
pression or epilepsy; severe and frequent head-
aches; diabetes mellitus; active liver disease or
jaundice; regular treatment with enzyme-inducing
drugs, such as barbiturates, phenytoin, carbama-
zepine or rifampicin; blood pressure greater than
160 mmHg systolic or 100 mmHg diastolic; bloody
breast discharge; severe hirsutism; pregnancy or
suspected pregnancy; current evidence of pelvic
Vol 4, No 4
October 2016 A randomized five year comparative study  191
inflammatory disease; and participation in another
clinical study on the previous three months.
Study Endpoints
The primary efficacy variable was the pregnancy
rate calculated using the Kaplan-Meier product
limit method. Secondary efficacy parameters were
the alteration in menstrual cycles, discontinuation
or continuation rates, rates of implant removal due
to menstrual problems and/or medical reasons,
and the duration of implant insertion and removal
from asepsis to wound closure. All data were based
on the information reported by the women using
Jadena® or Norplant®. We also investigated several
safety parameters including laboratory parame-
ters, general state of health, adverse events, con-
comitant medications, body weight, and vital signs.
Data Management and Analyses
All variables were described according to their
types using univariate statistics (mean and stand-
ard deviation for continuous data, frequency and
percentage for categorical data). The primary effi-
cacy variable in this trial was the pregnancy rate
estimated using the Kaplan-Meir product limit
method. The two treatment groups were compared
using the Wilcoxon rank-sum test. A significance
level (-level) of 0.05 was used for all statistical
tests. Secondary and safety variables were pre-
sented descriptively. 
RESULTS
There were 600 women enrolled in this study.
They were randomized to receive Jadena® (301
women) or Norplant® (299 women). Their mean
age was 29.8 (SD 5.3) years old, ranging from 18
to 40 years old. Subjects using Norplant® were
older than subjects using Jadena® (p=0.008). On
the average; however, the women from both im-
plant groups were relatively similar to the demo-
graphic characteristics, such as body weight, body
mass index (BMI), and blood pressure (Table 1).
All subjects had normal body weight and BMI. All
subjects had been pregnant and/or had delivered
at least once. The mean number of previous preg-
nancies were 2.8 (SD 1.5). The mean number of
live birth were 2.6 (SD 1.4). Higher parity was ob-
served in women on Jadena® than Norplant®
(p=0.04). At baseline, most women (87.6%) re-
ported normal or usual menstrual pattern. Five-
point four percent of these women had amenor-
rhea. Almost one-third (32.5%) of the subjects
wanted more children. The most popular (49.8%)
contraceptive method used prior to the study en-
rollment was the combination of oral contraceptive
and majority of them (38.7%) had their last con-
traceptive used less than 31 days before. More than
half of the women (60.3%) did not practice breast-
feeding. Almost all subjects (95%) reported vaginal
delivery at the last pregnancy. Cytological exami-
nation data were available in 591 subjects. The re-
sults were mostly classified into CI (75.1%), while
CII was found in 24.2% of women. None was clas-
sified as CIII.
Efficacy Assessment 
Primary end point
No pregnancy was observed in both contraceptive
users. However, an intrauterine pregnancy was
found in Norplant® group which had been con-
firmed that it started before her enrollment into
the study. The implant was removed immediately
and she delivered a baby spontaneously at term
gestational age. The Kaplan-Meier product limit
method showed that non-pregnancy probabilities
were not different between the two implants (Ta-
ble 2). Therefore, both contraceptive methods
showed similar efficacy in controlling pregnancy
over 5 years.
Secondary endpoints
The prevalence of dysmenorrhea was considered
low. The prevalence was not significantly different
between baseline and after 5 years both in women
using Jadena® (2.0% vs. 2.5%; p=0.812) and Nor-
plant® (2.4% vs. 2.0%; p=0.977). The menstrual
changes occurred in majority of subjects in the first
two years. Improvement of menstrual irregulari-
ties increased after three years. The pattern of
menstrual changes was similar between Jadena®
and Norplant® users (Figure 1).
Discontinuation or continuation rates
At the end of the third year and after obtaining
written consent to extend the observation period
by an additional 2-year, 411 of the 600 women
(68.5%) agreed to continue the study; consisting
of 210 women using Norplant® (70.2%) and 201
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women using Jadena® (66.8%). Continuation rates
per year were shown on Table 3. The difference in
discontinuation rates between the two contracep-
tive methods from year-1 to year-5 was not signifi-
cantly different (p=0.746).
Rates of implant removal due to menstrual pro-
blems and/or medical reasons
Premature removal of the implant was decided by
154 out of 217 women. The reason mostly was
because of the desire to get pregnant (19.4%).
Others had menstrual problems, such as metro-
rrhagia (4.1%), amenorrhea (3.2%), spotting
(2.3%), prolonged menstrual flow (1.8%), and
heavy menstrual flow (1.4%). The details on the
primary reasons for implant removal in both
groups were given on Table 4.
Duration of the implant placement and removal
Nearly all subjects (99.2%) had their implant
placed on their left upper arm. There were neither
reported complications nor difficulties encoun-
tered during implant placement. From aseptic to
skin closure, the surgical procedure took an aver-
age of 3.1 (SD 1.5) minutes, varied from as short
as 1 minute to as long as 10 minutes. The proce-
dure for Jadena® placement was shorter than Nor-
plantS® (2.2 (SD 0.9) vs. 4.1 (SD 1.3) minutes;
p<0.001).
The surgical procedure for implant removal took
an average of 8.7 (SD 4.9) minutes. Procedures for
Jadena® removal was significantly shorter than
Norplant® removal (6.4 (SD 4.1) vs. 10.5 (SD 4.7)
minutes; p<0.001). Most subjects (89.5%) did not
feel any complication during the procedure.
Safety Assessment
During the 5-year period, 37 (6.2%) of subjects
experienced at least one adverse event (AE), com-
prising 20 (6.6%) women on Jadena® and 17
(5.9%) women on Norplant®. Most AEs (64.9%)
was mild; however, 6 women (16.2%) experienced
moderate AEs, which all belonged to Jadena®
group. Two patients had severe AEs; one on Nor-
plant® was diagnosed with severe hypertension
during visit-11 and the another one on Jadena® ex-
perienced severe cramping on the arm at visit-11
which requested to be removed. One woman on
Jadena® died due to dengue hemorrhagic fever
(DHF) and it was not related to the contraceptive
method.
Adverse events reported by women using
Jadena® included spotting (5 women), bleeding (3
women), influenza (2 women), dizziness (2 wo-
men), expulsion (1 woman), cardiomegaly (1 wo-
man), cramp at the implant site (1 woman), death
due to DHF (1 woman), headache (1 woman), local
infection (1 woman), menometrorrhagia (1 wo-
man), metrorhagia (1 woman), and numbness (1
woman). In women using Norplant®, the adverse
events were headache (5 women), spotting (3
women), hypertension (2 women), influenza (2
women), local infection (2 women), abscess (1
woman), bleeding (1 woman), dizziness (1 wo-
man), emesis gravidarum (1 woman), irregular
bleeding (1 woman), numbness (1 woman), palpi-
tation (1 woman), pelvic pain/dyspareunia (1 wo-
man), and sweating (1 woman).
DISCUSSION
In the beginning, this study was designed for 3
years, but it was extended for another 2-year to
complete a 5-year observation of both implant sys-
tem. The first study on extended use (5 years) of
the two-rod implants (Norplant II®) was conducted
in China, with a failure rate of 0.65 per 100 users
and continuation rate of 65.3 per 100 users. These
rates were similar to that of the capsule implant
users.8 Continuation of two-rod LNG implants has
also been tried in US study when the 3-year cumu-
lative pregnancy rate was 0.8 per 100.10 For a 5-
year period, the 2-rod LNG implants were equiva-
lent to the 6-capsule LNG implants regarding to
safety and efficacy parameters. It offers the advan-
tage to insert more easily and remove more ra-
pidly.10 The cumulative 5-year pregnancy rate of
LNG implants was comparable to that of tubal li-
gation.11
Our study subjects were older (29.8 years old)
than the US study, which had the mean age at base-
line of 25.5 years old.10 This could be because all
subjects in our study was married women who had
given delivering at least once. It also reflects that
contraceptive use is uncommon in young, unmar-
ried women adults in Indonesia. Other charac-
teristics in this study were the subjects’ body
weight and BMI, which showed the normal range.
On the contrary, subjects in the US study showed
much higher body weight with a mean of 62.4 kg
at baseline.10 Weight gain is an important problem
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during implant use; thus, it should be considered
since the beginning.
The primary reason for discontinuation after
three years of use was the subjects’ plan for preg-
nancy. However, a substantial number of subjects
(more than 70%) also experienced menstrual pro-
blems. Menstrual irregularities (lighter or heavier
menstrual flow and amenorrhea) were occurred in
most subjects at the first year of use. Although
menstrual change was common, most subjects de-
cided to continue the implants. The overall level of
satisfaction was high and even the continuation
rates at the end of the first year were better than
combined oral contraception.12 Menstrual change
was also reported as the common AE during the
first year of Norplant® use in Singapore. However,
these menstrual irregularities appeared to be re-
duced as the time and they were tolerated since
97% of the women continued at the end of the first
year.13 Study on bleeding patterns on 234 Nor-
plant® users for 5 years showed that a substantial
number of subjects (66.3%) had irregular cycles
during the first year and 7.1% were amenorrhea.
However, by the fifth year of use, only 37.5% sub-
jects had irregular cycles and none had amenor-
rhea. Thus, the menstrual irregularity improved af-
ter the first year of use.14
In a minority of subjects, prolonged bleed-
ing/spotting (8.2%) and irregular bleeding (5.6%)
were the primary reasons for removal.10 A study
among Norplant® users in Europe found that dis-
continuation before 5 years of implant was related
mostly to irregular bleeding.15 Risk factors for Nor-
plant® discontinuation for perceived menstrual
problems were higher education level (more than
12 years), had used no contraceptive in the pre-
ceding month before Norplant® insertion, or had a
relatively long duration of menstrual flow at ad-
mission.16 Discontinuation rate due to menstrual
problems increased from 9.4 per 100 women at the
end of year-2 to 16.4 per 100 women at the end
of year-5.16
In a phase III clinical trial, the 2-rod subdermal
implants showed high continuation rates, such as
88.1% at 1 year of use and 73.5% after 2 years.
The main reason for discontinuation was men-
strual disturbance, mainly prolonged bleeding.17
Menstrual irregularity with the 2-rod system was
not significantly different from that observed with
Norplant®. Normal menstrual bleeding was un-
common during the first three months of use, but
the prevalence increased to almost 70% at the end
of five years. Amenorrhea was uncommon after
two years of use.18
Removal due to headache (4.7%) and weight
gain (4.0%) were the next most frequent medical
reasons after menstrual problem in US study.10 In
our study, only three subjects asked the implants
remove for headache and one subject for having
weight gain. Increased body weight of 1 kg per year
on average was observed in implant users.11
Higher body weight gain of 2.9 kg was observed in
intrauterine LNG device at 12 months.19
Other rare adverse effects that might be a medi-
cal concern were local infection and hypertension.
Local infection was rare (0.4 per 100 users at 24
months) in the phase III clinical trial of 2-rod im-
plant.17 A study among 2,674 Norplant® acceptors
from 7 countries and followed for one year showed
that the incidence rate of infection was low (0.8%).
Insertion site infection and implant expulsion were
reported after the first two months of use.20 A
study on 267 Norplant® users showed that neither
systolic nor diastolic blood pressures were af-
fected. Increasing blood pressure was more likely
to be associated with the women’s age, obesity and
family history of hypertension.21
In this study, Jadena® use was associated with
significant shorter time of insertion and removal.
In a 3-year randomized, controlled study, implant
removal of the 2-rod system took about half the
time required for 6-capsule implants (p<0.001).22
Difficult implants removal might be occurred in
about 3% subjects due to deeply placed or poorly
aligned implant or severe reaction to local anes-
thetic agent.11 Implant removal was more difficult
than insertion because in step of time, fat and fi-
brous tissue could develop around the capsules.
Delayed removal of implant could be seen in many
Norplant® users in Indonesia. A large study invol-
ving 2,979 Indonesian women using Norplant® in
14 provinces showed that 66% of the women had
implant removal by the end of the fifth year (90%
by sixth year).23 Therefore, the 2-rod implant sys-
tem which was easier to insert could potentially
reduce the difficulties during implant removal after
a long period of use.
Cervical cytology might be a concern among
women who used long-term hormonal contracep-
tion. However, subdermal LNG implant has been
proved to be safe during five years of use.24 In this
study, there was no abnormal cytology or cervical
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Table 1. The Characteristics of the Study Subjects (n=600)
Jadena® (n=301) Norplant® (n=299)
Age, years (mean (SD)) 28.8 (1.3) 30.0 (1.7)
Body weight, kg (mean (SD)) 50.7 (2.3) 50.9 (2.1)
Body mass index, kg/m2 (mean (SD)) 21.9 (0.6) 22.1 (0.6)
Systolic blood pressure, mmHg (mean (SD)) 112.9 (0.9) 113.4 (2.0)
Diastolic blood pressure, mmHg (mean (SD)) 73.8 (1.9) 73.6 (2.3)
Number of previous pregnancies (mean (SD)) 2.7 (0.4) 2.9 (0.4)
Parity (mean (SD)) 2.5 (0.4) 2.7 (0.3)
SD=standard deviation
Table 2. Kaplan-Meier Estimates for non-Pregnancy Probabilities*
Jadena® (n=301) Norplant® (n=299)
Probability SD Probability SD
Year 1 0.920 0.016 0.916 0.084
Year 2 0.890 0.018 0.886 0.018
Year 3 0.664 0.027 0.702 0.026
Year 4 0.651 0.027 0.692 0.027
Year 5 0.000 0.000 0.000 0.000
Median time 60 months 60 months
*Not significant at alpha 0.05; SD=standard deviation
Table 3. Continuation Rates of using Levonorgestrel Contraceptive Implant
Year 1 Year 2 Year 3 Year 4 Year 5
n % n % n % n % n %
Jadena® (n=301) 287 95.3 274 91.1 201 66.8 199 66.1 185 61.5
Norplant® (n=299) 282 94.3 273 91.3 210 70.2 208 69.6 198 66.2
Table 4. Primary Reasons for Discontinuation (Implant Removal) after Three Years*
Primary reason Jadena® Norplant® Total
No reason indicated 25 32 57
Intrauterine pregnancy 0 1 1
Menstrual problems
Frequent irregular bleeding 4 4 8
Heavy menstrual flow 2 1 3
Prolonged menstrual flow 1 2 3
Amenorrhea 3 4 7
Spotting 4 1 5
Placement problems
Infection at site 1 4 5
Expulsion of 1 or more implants 1 2 3
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change to lead to premature removal or discon-
tinuation of both implant systems.
CONCLUSION
The new 2-rod LNG subdermal system (Jadena®)
showed similar efficacy with the old 6-capsule LNG
subdermal system (Norplant®) in term of birth
control. Both implants system also have similar
tolerability profile. Jadena® is easier to insert and
remove than Norplant®.
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